Q&A: Could a tiny ear device help ease depression?

A new UVA center has opened enrollment for its first clinical study, which is testing an ear device that gently stimulates the vagus nerve as a way to ease depression, anxiety and poor sleep in people receiving addiction treatment.

The Center for Neuromodulation Research was founded in 2025. Daisy Thompson-Lake, an assistant professor of psychiatry and neurobehavioral sciences, co-leads the center and recently led one of the first reviews of noninvasive vagus nerve stimulation as a treatment for addiction, published in Drug and Alcohol Dependence. 

Daisy Thompson-Lake's headshot

Daisy Thompson-Lake teaches in the UVA School of Medicine. (Contributed photo)

She spoke with UVA Today about the center, the new study and where the field is heading.

Q. What do you do at UVA?

A. I am the associate director of the Center for Neuromodulation Research, directed by James Mahoney. We set this up when we moved here from West Virginia University last year. Neuromodulation means changing how brain circuits work by delivering targeted energy, such as gentle electrical pulses or sound waves, to specific nerves or brain regions. Our center develops and tests these treatments for addiction and other psychiatric conditions.

We work in three main areas. The first is low-intensity focused ultrasound, which uses sound waves to reach deep brain regions involved in reward and craving, without surgery and without damaging tissue. The second is (vagus nerve stimulation), which we can deliver through the ear. The third is brain imaging, using MRI to see how the brain changes with treatment and to choose the best targets.

At West Virginia University, we were part of the teams that carried out some of the first studies of focused ultrasound and deep brain stimulation as treatments for addiction. The move to UVA was small geographically, but big scientifically. UVA has a long history in focused ultrasound, and the Focused Ultrasound Foundation is based right here in Charlottesville. Here we can grow from one or two techniques into a full research program, with a strong focus on noninvasive treatments that could one day be used outside the hospital, and even at home.

Q. How have you spent your first year?

A. Building the foundations. A new center needs equipment, partnerships, staff and approved study protocols before the first participant walks through the door.

For our (vagus nerve stimulation) study, I approached Parasym, a medical device company based in London, and they agreed to provide their devices free of charge. This will be the first time their device has been tested in people being treated for addiction.

We also worked with UVA’s Data Analytics Center to set up a master infrastructure system to roll out across all studies at the center and build MRI pipelines, and with the Mobile AI for People Lab to build a smartphone app for the study. Each day it reminds participants to use their device and asks a few short questions about mood, sleep and craving. That lets us see how people are doing day-to-day, not just during clinic visits.

Q. You’ve just launched your first clinical study. What can you tell us about it?

A. It is a pilot study designed to tell us whether the treatment is safe, comfortable and practical for people to use, and whether it shows enough promise to test in a larger trial. 

We are enrolling adults aged 18 to 60 who are in outpatient treatment for drug use. Participants use the device at home for one hour a day for 30 days and come in for five study visits. They are compensated for their time.

The device is a small earpiece that clips onto the tragus, the small flap at the front of your ear. A branch of the vagus nerve runs close to the skin there, so we can stimulate it gently without any surgery. 

We expect that daily stimulation will reduce depression and anxiety and improve sleep. These problems are very common in people in recovery, and they are some of the main reasons people struggle to stay in treatment. 

Anyone interested in this study, or in other center studies that will open soon, can complete a short screening survey. 

Q. How does this study fit into the bigger picture?

A. (Vagus nerve stimulation) has become quite trendy, but it has a long scientific history. An implanted device, placed in the neck, was approved by the U.S. Food and Drug Administration for treatment-resistant depression in 2005. That approach needs surgery, but with new technology we can reach the vagus nerve through the skin. One ear-based device has already been cleared by the FDA to ease opioid withdrawal symptoms.

Give Where You Live, Support our local non-profits Act Now
Give Where You Live, Support our local non-profits Act Now

The vagus nerve is the main communication line between the brain and the body’s organs. It is also a key part of the body’s “rest and digest” system, which balances our “fight or flight” stress response.

In addition, that stress response is often stuck in overdrive. By gently stimulating the vagus nerve, we aim to strengthen its calming signal to the brain, telling it, “Everything’s fine. We can relax.” The goal is to help shift the brain and body out of constant fight-or-flight and into a calmer, more balanced state.

You can read more about UVA’s scientific breakthroughs and health advances at the Office of the Vice President for Research’s news page.

Media Contacts

Zeina Mohammed

University News Associate University Communications